CMMB vs. EFTR, CANF, TRVN, TENX, KTTA, PULM, GRAY, IBIO, UPC, and SBFM
Should you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include eFFECTOR Therapeutics (EFTR), Can-Fite BioPharma (CANF), Trevena (TRVN), Tenax Therapeutics (TENX), Pasithea Therapeutics (KTTA), Pulmatrix (PULM), Graybug Vision (GRAY), iBio (IBIO), Universe Pharmaceuticals (UPC), and Sunshine Biopharma (SBFM). These companies are all part of the "pharmaceutical preparations" industry.
eFFECTOR Therapeutics (NASDAQ:EFTR) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation.
eFFECTOR Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500.
eFFECTOR Therapeutics received 9 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. Likewise, 79.31% of users gave eFFECTOR Therapeutics an outperform vote while only 58.33% of users gave Chemomab Therapeutics an outperform vote.
Chemomab Therapeutics' return on equity of 0.00% beat eFFECTOR Therapeutics' return on equity.
eFFECTOR Therapeutics presently has a consensus price target of $24.00, suggesting a potential upside of 1,197.30%. Chemomab Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 944.78%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe eFFECTOR Therapeutics is more favorable than Chemomab Therapeutics.
In the previous week, eFFECTOR Therapeutics and eFFECTOR Therapeutics both had 1 articles in the media. Chemomab Therapeutics' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.
Chemomab Therapeutics has lower revenue, but higher earnings than eFFECTOR Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.
57.7% of eFFECTOR Therapeutics shares are held by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are held by institutional investors. 8.4% of eFFECTOR Therapeutics shares are held by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
eFFECTOR Therapeutics beats Chemomab Therapeutics on 9 of the 13 factors compared between the two stocks.
Get Chemomab Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chemomab Therapeutics Competitors List
Related Companies and Tools
